新华制药(000756) - 2015 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥35,920,180.90, representing a significant increase of 339.68% year-on-year[7]. - Operating revenue for the reporting period was ¥824,916,548.09, a decrease of 8.16% compared to the same period last year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥24,593,667.42, up 735.04% year-on-year[7]. - Basic earnings per share increased to ¥0.08, a rise of 300.00% compared to the same period last year[7]. - The company reported a net profit of CNY 529,280,048.13, an increase from CNY 482,238,546.28, representing a growth of about 9.7%[30]. - The net profit attributable to shareholders of the parent company was CNY 35,920,180.90, up from CNY 8,169,600.38 year-on-year[36]. - Net profit for the current period is $69,778,409.73, up from $62,486,144.59, which is an increase of about 11.6%[44]. - The company reported a total profit of $92,172,233.11, compared to $81,890,270.18 in the previous period, an increase of about 12.5%[44]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,439,259,394.35, an increase of 4.57% compared to the end of the previous year[7]. - Current liabilities decreased to CNY 1,495,331,117.74 from CNY 1,601,089,900.43, a reduction of about 6.6%[29]. - Long-term borrowings rose to CNY 846,049,318.00, an increase of 33% compared to CNY 635,948,545.00 in the previous period[29]. - Total liabilities increased to CNY 2,508,652,071.78 from CNY 2,333,280,726.09, reflecting an increase of approximately 7.5%[29]. - Total equity decreased slightly to CNY 1,793,458,183.79 from CNY 1,798,502,114.06[36]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥202,238,053.59, down 17.17% compared to the previous year[7]. - The net cash flow from operating activities for Q3 2015 was CNY 202,238,053.59, a decrease of 17.2% compared to CNY 244,158,817.99 in the same period last year[51]. - Total cash inflow from operating activities was CNY 1,948,879,272.02, while cash outflow was CNY 1,746,641,218.43, resulting in a net inflow of CNY 202,238,053.59[51]. - The net cash flow from investing activities was -CNY 86,005,540.83, compared to -CNY 226,108,765.74 in the previous year, indicating an improvement[52]. - Cash inflow from financing activities was CNY 744,765,701.02, an increase of 12.2% from CNY 663,522,904.68 in the same period last year[52]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,575[10]. - The largest shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., holds 34.46% of the shares[10]. Government Subsidies and Other Income - The company received government subsidies amounting to ¥14,502,033.77 during the reporting period[8]. - The company's deferred income rose by 49.74% to RMB 82,723 thousand, mainly due to increased government subsidies for engineering projects[15]. Investment and Expenses - The company’s investment income decreased by 30.62% to RMB 5,231 thousand, primarily due to last year's gains from the sale of equity stakes[16]. - The company experienced a significant increase in sales expenses, which rose to CNY 80,229,183.68 from CNY 73,530,009.38[36]. - The company paid CNY 330,245,243.21 to employees, which is an increase of 18.3% from CNY 279,309,093.28 in the previous year[51]. Future Plans - The company plans to issue A-shares and implement an employee stock ownership plan, pending regulatory approvals[17].